Jasper Therapeutics, Inc. (JSPR)
Data as of , from SEC Form 4 filings.
Net insider buying (90d)Watch JSPR
See up to 3 months of JSPR. The 7-day demo opens the 1M and 3M ranges and puts JSPR on your watchlist.
Start 7-day demoLatest JSPR insider trades
Matthew E. Ros - OfficerOpen-market purchase881 sh- Patrick J. Crutcher - DirectorOpen-market purchase888 sh
About Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc. is an SEC registrant, filing under CIK 0001788028, classified as biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
JSPR Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 1,769 | - |
| Grant or award | 6 | 52,500 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
JSPR insider transactions (Form 4)
3225 Form 4 filings on record, the earliest from Dec 12, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Thomas G. Wiggans - Director | Grant or award | Stock Option (Right to Buy | 7,500 | $0.00 | - | |
| Svetlana Lucas - Director | Grant or award | Stock Option (Right to Buy | 7,500 | $0.00 | - | |
| Patrick J. Crutcher - Director | Grant or award | Stock Option (Right to Buy | 7,500 | $0.00 | - | |
| Kurt von Emster - Director | Grant or award | Stock Option (Right to Buy | 7,500 | $0.00 | - | |
| Judith Anne Shizuru - Director | Grant or award | Stock Option (Right to Buy | 7,500 | $0.00 | - | |
| Matthew E. Ros - Officer | Open-market purchase | Non-Voting Convertible Preferred Stock | 881 footnote F1,F2 | - footnote F1,F2 | - | |
| ||||||
| Patrick J. Crutcher - Director | Grant or award | Stock Option (Right to Buy | 15,000 | $0.00 | - | |
| Patrick J. Crutcher - Director | Open-market purchase | Non-Voting Convertible Preferred Stock | 888 footnote F2,F3 | - footnote F2,F3 | - | |
| ||||||
| Jeetinder Singh Mahal - Officer | Grant or award | Stock Option (right to buy) | 500,000 | $0.00 | - | |
 Ron Martell - Officer | Grant or award | Stock Option (right to buy) | 234,000 | $0.00 | - | |
| Jeetinder Singh Mahal - Officer | Grant or award | Stock Option (right to buy) | 90,000 | $0.00 | - | |
| Herb Cross - Officer | Grant or award | Stock Option (right to buy) | 90,000 | $0.00 | - | |
| Thomas G. Wiggans - Director | Open-market purchase | Voting Common Stock | 41,000 | $2.43 | $100K | |
| Thomas G. Wiggans - Director | Open-market purchase | Common Stock Warrant (right to buy) | 41,000 | - | - | |
| Svetlana Lucas - Director | Open-market purchase | Voting Common Stock | 20,000 | $2.43 | $49K | |
| Svetlana Lucas - Director | Open-market purchase | Common Stock Warrant (right to buy) | 20,000 | - | - | |
| Ron Martell - Officer | Open-market purchase | Voting Common Stock | 41,000 | $2.43 | $100K | |
| Ron Martell - Officer | Open-market purchase | Common Stock Warrant (right to buy) | 41,000 | - | - | |
| Judith Anne Shizuru - Director | Open-market purchase | Voting Common Stock | 41,000 | $2.43 | $100K | |
| Judith Anne Shizuru - Director | Open-market purchase | Common Stock Warrant (right to buy) | 41,000 | - | - | |
| Scott C. Brun - Director | Grant or award | Stock Option (right to buy) | 7,500 | $0.00 | - | |
| Judith Anne Shizuru - Director | Grant or award | Stock Option (right to buy) | 7,500 | $0.00 | - | |
| Vishal Kapoor - Director | Grant or award | Stock Option (right to buy) | 7,500 | $0.00 | - | |
| Chris Nolet - Director | Grant or award | Stock Option (right to buy) | 7,500 | $0.00 | - | |
| Svetlana Lucas - Director | Grant or award | Stock Option (right to buy) | 7,500 | $0.00 | - | |
| Kurt von Emster - Director | Grant or award | Stock Option (right to buy) | 7,500 | $0.00 | - | |
| Thomas G. Wiggans - Director | Grant or award | Stock Option (right to buy) | 7,500 | $0.00 | - | |
| Herb Cross - Officer | Grant or award | Stock Option (right to buy) | 90,000 | $0.00 | - | |
| Ron Martell - Officer | Grant or award | Stock Option (right to buy) | 234,000 | $0.00 | - | |
| Jeetinder Singh Mahal - Officer | Option exercise | Voting Common Stock | 900 | $7.10 | $6K | |
| Jeetinder Singh Mahal - Officer | Open-market sale | Voting Common Stock | 900 | $22.11 | $20K | |
| Jeetinder Singh Mahal - Officer | Option exercise | Stock Option (right to buy) | 900 | $0.00 | - | |
Item 8.01, 9.01
Item 5.07
Item 9.01
Item 5.02
JSPR insider trading FAQ
What is the latest insider trade for JSPR?
Jasper Therapeutics, Inc. (JSPR) had 7 insider filings in the last 90 days, with the most recent on 2026-08-04. The full record for JSPR runs to 25 Form 4 filings, the earliest from 2024-12-12. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying JSPR stock?
2 insider purchases of JSPR were filed in the last 90 days.
How many insiders are selling JSPR stock?
No insider sales of JSPR were filed in the last 90 days. 1 sale is on record for this company.
Where can I see JSPR SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects JSPR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Thomas G. Wiggans view on EDGAR
- - Svetlana Lucas view on EDGAR
- - Patrick J. Crutcher view on EDGAR
- - Kurt von Emster view on EDGAR
- - Judith Anne Shizuru view on EDGAR
- - Matthew E. Ros view on EDGAR
- - Patrick J. Crutcher view on EDGAR
- - Jeetinder Singh Mahal view on EDGAR
- - Ron Martell view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where JSPR's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow JSPR with a 7-day demo
- JSPR on your watchlist
- Every JSPR Form 4 filing on record
- Up to 3 months of JSPR price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
